Back to Newsroom

Cempra’s Solithromycin (CEM-101) Receives Qualified Infectious Disease Product Designation From the U.S. Food and Drug Administration

CHAPEL HILL, N.C., Sept. 6, 2013 — Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has designated oral Solithromycin (CEM-101), as a Qualified Infectious Disease Product (QIDP) for the indication of community-acquired bacterial pneumonia.